Abrocitinib tablets are a Janus kinase (JAK) inhibitor indicated for the treatment of adults and pediatric patients aged 12 years and older with refractory moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products (including biologics) or for whom these therapies are not advisable. 

Use Restriction: Co-administration of abrocitinib tablets with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants is not recommended.

The recommended dosage is 100 mg once daily. If 100 mg of abrocitinib tablets once daily does not achieve an adequate response, consider increasing the dosage to 200 mg once daily. If 200 mg once daily does not achieve an adequate response, discontinue the drug. Use the minimum effective dose to maintain the response. 

Abrocitinib tablets can be used with or without topical corticosteroids. If a dose is missed, administer it as soon as possible unless it is less than 12 hours until the next dose, in which case the missed dose should be skipped. Thereafter, resume administration at the specified time.